Perrigo gets acne treatment approval

The lotion had sales of $15 million in the past year.

Pharmaceutical firm Perrigo Company (Nasdaq:PRGO; TASE:PRGO) said it has received final approval from the US Food and Drug Administration (FDA) for its version of a Sanofi-Aventis acne medication, Klaron.

Perrigo can begin to market Sulfacetamide Sodium Topical Suspension, 10% (Lotion). Perrigo's version is therapeutically equivalent to the Klaron (10%) lotion developed by Sanofi-Aventis. Klaron is used for the topical treatment of acne.

Klaron lotion had sales of approximately $15 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) also received FDA approval last week for an acne treatment, Solodyn, but reached an agreement with Medicis, the developer, to wait until 2011 to market its version, in return for Medicis dropping legal claims against Teva.

Perrigo chairman and CEO Joseph C. Papa said, "This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter."

Perrigo develops, manufactures, and sells over the counter and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products.

Shares in Perrigo closed at $22.95, up 2.8%. Its market cap is $2.11 billion.

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017